Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $43.17.

A number of research analysts have weighed in on ORKA shares. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, December 20th. Stifel Nicolaus started coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. Finally, Wedbush restated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $1,037,000. FMR LLC acquired a new stake in shares of Oruka Therapeutics during the third quarter valued at about $114,763,000. Great Point Partners LLC purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $12,614,000. Braidwell LP acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $12,640,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 2.8 %

NASDAQ:ORKA opened at $12.25 on Tuesday. The stock has a market capitalization of $428.75 million, a P/E ratio of -1.96 and a beta of 0.81. Oruka Therapeutics has a twelve month low of $12.23 and a twelve month high of $53.88. The stock has a 50-day simple moving average of $20.09.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.